AZD8186, a potent and selective inhibitor of PI3Kb/d, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Authors
de Bono, JSHansen, A
Choudhury, AD
Cook, Natalie
Heath, EI
Higano, C
Linch, M
Martin-Liberal, J
Rathkopf, DE
Wisinski, KB
Barry, S
de Bruin, E
Brugger, W
Colebrook, S
Klinowska, T
Moschetta, M
Mortimer, PGS
Siu, LL
Shapiro, G
Affiliation
The Institute of Cancer Research and Royal Marsden, London, UKIssue Date
2018
Metadata
Show full item recordCitation
de Bono JS, Hansen A, Choudhury AD, Cook N, Heath EI, Higano C, et al. 833P AZD8186, a potent and selective inhibitor of PI3K?/?, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy284.042PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy284.042Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy284.042